for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Guerbet SA

GRBT.PA

Latest Trade

47.10EUR

Change

0.60(+1.29%)

Volume

5,515

Today's Range

46.15

 - 

47.65

52 Week Range

45.25

 - 

59.80

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
46.50
Open
47.00
Volume
5,515
3M AVG Volume
0.13
Today's High
47.65
Today's Low
46.15
52 Week High
59.80
52 Week Low
45.25
Shares Out (MIL)
12.57
Market Cap (MIL)
592.58
Forward P/E
14.37
Dividend (Yield %)
1.80

Next Event

Guerbet SA Annual Shareholders Meeting

Latest Developments

More

Guerbet Signs Icobrain Distribution Agreement With Icometrix

Guerbet H1 EBITDA Up At 61.6 Million Euros

Guerbet Signs New Agreement With IBM Watson Health On AI Solution

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Guerbet SA

Guerbet SA is a France-based pharmaceutical group specialized in the manufacture and marketing of medical imaging contrast agents destined for diagnostic purposes. It produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents are used in the diagnosis of cardio-vascular, inflammatory and neuro-degenerative disorders. The Company’s portfolio of products comprises brands, such as Xenetix, Hexabrix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol, among others. Guerbet SA is also active in the fine chemicals industry through its Simafex subsidiary. The Company operates through its subsidiaries, including Simafex, Medex, SCI KALB, Guerbet LLC, Guerbet Asie Pacifique and Guerbet GmbH, among others.

Industry

Biotechnology & Drugs

Contact Info

15 rue des Vanesses, Zone Paris Nord II

+33.1.45915000

http://www.guerbet.com

Executive Leadership

Marie-Claire Janailhac-Fritsch

Independent Chairman of the Board

Yves L'Epine

Chief Executive Officer, Member of the Executive Committee, Director

Pierre Andre

Deputy Chief Executive Officer

Jean-Francois Le Martret

Chief Financial & Administrative Officer, Senior Vice President, Member of the Executive Committee

Claire Corot

Senior Vice President, Research, Innovation and Business Development Licensing, Member of the Executive Committee

Key Stats

2.00 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.8K

2017

0.8K

2018

0.8K

2019(E)

0.8K
EPS (EUR)

2016

2.960

2017

3.670

2019(E)

3.278
Price To Earnings (TTM)
13.81
Price To Sales (TTM)
0.74
Price To Book (MRQ)
1.61
Price To Cash Flow (TTM)
5.88
Total Debt To Equity (MRQ)
117.95
LT Debt To Equity (MRQ)
92.48
Return on Investment (TTM)
6.05
Return on Equity (TTM)
4.13

Latest News

Latest News

BRIEF-Guerbet: Transition From Temporary Importation To Regular Supply For Lipiodol Injection

* GUERBET LLC USA ANNOUNCED ON MONDAY TRANSITION FROM TEMPORARY IMPORTATION TO REGULAR SUPPLY FOR LIPIODOL (ETHIODIZED OIL) INJECTION; ALSO INTRODUCES NEW GLASS VIAL CONTAINER

BRIEF-Guerbet Announces Acquisition Of A New Microsphere Technology

* GUERBET ANNOUNCES THE ACQUISITION OF A NEW MICROSPHERE TECHNOLOGY TO STRENGTHEN ITS INTERVENTIONAL IMAGING RANGE

BRIEF-Guerbet Expects 2018 Revenue In-Line With 2017

* FOR 2018, EXPECTS REVENUE IN-LINE WITH 2017 AT CONSTANT EXCHANGE RATES

BRIEF-Guerbet Q1 Revenue Stable At 196.5 Million Euros

* Q1 REVENUE EUR 196.5 MILLION VERSUS EUR 197.3 MILLION YEAR AGO

BRIEF-Guerbet Partners With Lausanne’S CHUV And CET To Launch Clinical Study

* PARTNERS WITH LAUSANNE’S CHUV AND CET TO LAUNCH A CLINICAL STUDY

BRIEF-Guerbet FY EBITDA Increased By 22.4 Percent To 130 Million Euros

* FY NET INCOME EUR 46.2 MILLION VERSUS EUR 28.9 MILLION YEAR AGO

BRIEF-Guerbet: FY Revenue At Constant Exchange Rates Increases To 812.4 Million Euros

* REG-GUERBET : 2017 REVENUE AT CONSTANT EXCHANGE RATES: €812.4 MILLION; +4.7%

BRIEF-Guerbet Updates On MHLW Decision In Japan

* HAS IMMEDIATELY PROCEEDED TO REQUESTED REVISION OF PRECAUTIONS FOR MAGNESCOPE Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

BRIEF-Guerbet 9 months revenue up at 601.4 million euros

* 9 MONTHS REVENUE AT CURRENT EXCHANGE RATE EUR 601.4 MILLION VERSUS EUR 568.4 MILLION YEAR AGO

BRIEF-Guerbet H1 net income up at 23.1 million euros

* H1 NET INCOME EUR 23.1 MILLION VERSUS EUR 12.1 MILLION YEAR AGO

BRIEF-Guerbet announces CE mark for Vectorio

* REG-GUERBET ANNOUNCES CE MARK FOR VECTORIO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-FDA approves Guerbet’S Dotarem for patients younger than two years

* FDA APPROVES GUERBET’S DOTAREM (GADOTERATE MEGLUMINE) FOR PEDIATRIC PATIENTS YOUNGER THAN TWO YEARS Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

BRIEF-Guerbet H1 revenue rises to 407.1 million euros

* H1 REVENUE EUR 407.1 MILLION VERSUS EUR 376.7 MILLION YEAR AGO

BRIEF-Guerbet to phase out Hexabrix and Optimark sales globally

* WILL PHASE OUT SALES THROUGHOUT WORLD OF TWO PRODUCTS: HEXABRIX® (MEGLUMINE AND SODIUM IOXAGLATE) AND OPTIMARK® (GADOVERSETAMIDE).

BRIEF-Guerbet invests in Truffle Capital Fund

* GUERBET INVESTS IN TRUFFLE CAPITAL FUND DEDICATED TO MEDICAL DEVICES AND BIOTECHNOLOGIES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Guerbet Q1 revenue rises to 197.3 million euros

* Q1 revenue EUR 197.3 million ($214.54 million) versus EUR 183.7 million year ago

BRIEF-Guerbet FY net income down at 28.9 million euros

* FY net income 28.9 million euros ($31.2 million) versus 39.9 million euros year ago

BRIEF-Guerbet Q4 revenue rises to 207.4 million euros

* Q4 revenue 207.4 million euros ($219.93 million) versus 193.6 million euros year ago

BRIEF-Guerbet 9M sales falls 2.3 percent to 581.9 million euros

* 9 months sales fell 2.3 percent to 581.9 million euros ($633.5 million)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up